IGF-1 LR3

Dr. Yurth outlines a comprehensive stacking protocol for patients with muscle-building difficulty, fatigue, muscular dystrophy, or sarcopenia. The core stack includes creatine at 10 grams per day, CoQ10 with geranylgeranyl pyrophosphate (GGPP) for mitochondrial support, SS-31, urolithin A, and exogenous ketones. Peptide adjuncts include growth hormone secretagogues (CJC-1295, ipamorelin, tesamorelin), epitalon, BPC-157, and IGF-1 LR3 for severe cases. She frames this as applicable broadly — not just for muscular dystrophy but for anyone struggling with muscle building or fatigue.

Dr. Yurth explicitly states that the peptide and supplement protocol for muscular dystrophy is the same as what she uses for sarcopenic elderly patients or anyone struggling to build muscle, because the underlying mechanism — mitochondrial dysfunction — is shared. Muscular dystrophy is framed as an accelerated, genetically-driven version of the same mitochondrial failure seen in aging. This framing broadens the applicability of the SS-31, IGF-1 LR3, BPC-157, and GH secretagogue stack to a wide patient population.

Dr. Yurth outlines a comprehensive stacking protocol for patients with muscular dystrophy, sarcopenia, fatigue, or difficulty building muscle. The core stack includes: creatine at 10 grams per day, CoQ10 with geranylgeranyl pyrophosphate (GGPP) for mitochondrial support, SS-31 (elamipretide), urolithin A, and exogenous ketones. She notes growth hormone secretagogues (CJC, ipamorelin, tesamorelin, ibutamoren) and IGF-1 LR3 as additions for more severe cases, and BPC-157 for angiogenesis and muscle support. This stack is presented as applicable broadly to anyone struggling to build muscle or experiencing fatigue.

Dr. Yurth recommends IGF-1, specifically the longer-acting LR3 version, for severe muscle dysfunction such as that seen after prolonged hospitalization, injury, or muscular dystrophy. The mechanism described is that IGF-1 activates satellite cells, enabling new satellite cell formation and thus greater muscle building capacity. This mirrors the natural process where IGF-1 splits off during exercise. No specific dosage is mentioned.

The speaker contrasts IGF-1 DES with IGF-1 LR3 by emphasizing that DES's short half-life allows it to be cleared from the system before receptor desensitization can occur. This pharmacokinetic property is identified as the primary safety and efficacy advantage of DES over LR3. The speaker frames this as the mechanism by which DES delivers IGF-1 benefits without the associated receptor downregulation risk.

The speaker explicitly advises against stacking IGF-1 LR3 with HGH, arguing that the combination is counterproductive because IGF-1 LR3 causes receptor desensitization while HGH already maximizes endogenous IGF-1 production. The core argument is that IGF-1 LR3 adds receptor downregulation risk without meaningful additive benefit when HGH is already in use. This is presented as a practical clinical/coaching recommendation.

IGF-1 LR3 has a significantly longer half-life compared to endogenous IGF-1 or IGF-1 DES, which leads to desensitization of IGF-1 receptors. This receptor downregulation is presented as a key reason to avoid using IGF-1 LR3, particularly when stacked with exogenous HGH. The speaker frames this as a pharmacokinetic liability that negates the intended anabolic benefit.

The speaker includes significant cardiovascular disease as a condition requiring caution prior to IGF-1 LR3 use. This is presented alongside inflammatory conditions and uncontrolled diabetes as part of a comorbidity-based risk stratification approach. No specific cardiovascular parameters or dosage considerations are discussed. The recommendation reflects the speaker's clinical practice pattern.

The speaker flags uncontrolled diabetes as a condition warranting caution before using IGF-1 LR3. This is consistent with known IGF-1 axis interactions with insulin signaling and glucose metabolism. No specific glycemic thresholds or dosage modifications are provided. The caution is presented as part of a broader patient screening framework.

The speaker recommends exercising caution when considering IGF-1 LR3 use in patients who have active inflammatory conditions. This is presented as a clinical judgment call rather than an absolute contraindication. No specific inflammatory conditions are named, and no dosage adjustments are suggested. The warning is grouped alongside other comorbidity-based cautions.

The speaker issues a firm contraindication, stating that individuals with a personal or family history of hormone-sensitive cancers, or those with active neoplastic disease, should not use IGF-1 LR3 under any circumstances. This is framed as a hard stop with emphatic language ('full stop'). No dosage threshold is discussed as mitigating this risk. This represents the speaker's strongest safety warning in the transcript.

The speaker states there is no conclusive evidence that IGF-1 LR3 causes cancer, offering a measured qualification to the cancer concern. This is presented as a current state-of-evidence assessment rather than a citation of a specific trial or study. No dosage information is provided. The statement serves to contextualize risk without dismissing it.

The speaker explains that the same cellular pathways IGF-1 LR3 activates for muscle repair and cellular proliferation are the identical pathways that cancer cells exploit for growth. This mechanistic overlap is presented as the core biological concern with IGF-1 LR3 use. No specific dosage is mentioned in this context. The claim is framed as a mechanistic rationale rather than citing a specific study.

IGF-1 LR3 is presented as a modified, engineered analog of native IGF-1 specifically designed to circumvent the IGFBP sequestration problem. By reducing binding affinity to IGFBPs, IGF-1 LR3 is implied to have greater free bioavailability compared to regular IGF-1. No specific dosages, study citations, or clinical trial data are provided in this transcript excerpt.